SALT LAKE CITY, Utah, May 4, 2015 – Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in molecular diagnostic tests, today announced the launch of a digital media campaign to raise public health awareness about the role companion diagnostic tests play in enabling personalized medicine and precision medicine for patients with cancer.
The multi-media campaign, which features patients, doctors and Myriad employees, may be accessed online by visiting http://bit.ly/1Apm8nq or through social media by following the hashtags #personalizedmedicine, #precisionmedicine and/or #companiondiagnostics.
“Cancer is a complex array of diseases and there should not be a one-size-fits-all approach to treatment. Companion diagnostic tests provide us with insights into a patient’s individual biology, and that knowledge is power,” said Ron Rogers, executive vice president, Corporate Communications at Myriad. “Personalized medicine is a game changer, it’s the future of medicine. Our goal is to ensure that patients are getting the right drug at the right time and to avoid the trial-and-error treatment paradigm.”
The aim of this digital media campaign is to educate healthcare providers, cancer survivors, patient advocacy organizations, editors/journalists and social media followers about how companion diagnostics are being used in the fight against cancer. The campaign encourages people to learn more by going to http://bit.ly/1Apm8nq and sharing the information. Also, we recommend people craft their own messages and ask them to consider using the #personalizedmedicine, #precisionmedicine and #companiondiagnositcs hashtags.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions, and assess risk of disease progression and recurrence. Myriad is focused on strategic initiatives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, and expand internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G
###
Ron Rogers
Executive Vice President
Corporate Communications
Myriad Genetics Inc.
801-584-3065 (office)
908-285-0248 (cell)
@rogersro (Twitter)
Help employers find you! Check out all the jobs and post your resume.
The multi-media campaign, which features patients, doctors and Myriad employees, may be accessed online by visiting http://bit.ly/1Apm8nq or through social media by following the hashtags #personalizedmedicine, #precisionmedicine and/or #companiondiagnostics.
“Cancer is a complex array of diseases and there should not be a one-size-fits-all approach to treatment. Companion diagnostic tests provide us with insights into a patient’s individual biology, and that knowledge is power,” said Ron Rogers, executive vice president, Corporate Communications at Myriad. “Personalized medicine is a game changer, it’s the future of medicine. Our goal is to ensure that patients are getting the right drug at the right time and to avoid the trial-and-error treatment paradigm.”
The aim of this digital media campaign is to educate healthcare providers, cancer survivors, patient advocacy organizations, editors/journalists and social media followers about how companion diagnostics are being used in the fight against cancer. The campaign encourages people to learn more by going to http://bit.ly/1Apm8nq and sharing the information. Also, we recommend people craft their own messages and ask them to consider using the #personalizedmedicine, #precisionmedicine and #companiondiagnositcs hashtags.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions, and assess risk of disease progression and recurrence. Myriad is focused on strategic initiatives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, and expand internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G
###
Ron Rogers
Executive Vice President
Corporate Communications
Myriad Genetics Inc.
801-584-3065 (office)
908-285-0248 (cell)
@rogersro (Twitter)
Help employers find you! Check out all the jobs and post your resume.
